Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.
Li, Z., Partridge, J., Silva-Garcia, A., Rademacher, P., Betz, A., Xu, Q., Sham, H., Hu, Y., Shan, Y., Liu, B., Zhang, Y., Shi, H., Xu, Q., Ma, X., Zhang, L.(2017) ACS Med Chem Lett 8: 185-190
- PubMed: 28197309 
- DOI: https://doi.org/10.1021/acsmedchemlett.6b00384
- Primary Citation of Related Structures:  
5TJX - PubMed Abstract: 
A series of macrocyclic analogues were designed and synthesized based on the cocrystal structure of small molecule plasma kallikrein (pKal) inhibitor, 2 , with the pKal protease domain. This led to the discovery of a potent macrocyclic pKal inhibitor 29 , with an IC 50 of 2 nM for one olefinic isomer and 42.3 nM for the other olefinic isomer.
Organizational Affiliation: 
Global Blood Therapeutics , South San Francisco, California 94080, United States.